Despite challenges, the U.K.’s future is bright

In recent years the country had to deal with their formal exit from the European Union, COVID-19, four different prime ministers, and a major financial market blowup. The latest change in government also delivered plans to increase government spending through borrowing and higher corporate taxes… Read More

Haleon sale funds new acquisition

PFIZER INC. $49 is a buy. The prescription drugmaker (New York symbol PFE; Manufacturing & Industry sector; Shares outstanding: 5.6 billion; Market cap: $274.4 billion; Dividend yield: 3.3%; Takeover Target Rating: Medium; www.pfizer.com) merged its consumer drug business with GlaxoSmithKline (New York symbol GSK) in 2019.
Glaxo now plans to… Read More

Drugmaker opts for spinoff over sale

Pharmaceutical giant GlaxoSmithKline recently rejected a takeover offer from Unilever for its consumer drug business and will continue with its original plan to spin it off as a separate company.
The spinoff will let Glaxo better focus on its main prescription drug and vaccine operations. We… Read More

Spinoff spotlight

GLAXOSMITHKLINE PLC ADRs $46 is a spinoff buy. The company (New York symbol GSK; Manufacturing sector; ADRs outstanding: 2.7 billion; Market cap: $124.2 billion; Dividend yield: 4.7%; Takeover Target Rating: Medium; www.gsk.com) is a U.K.-based global healthcare firm that develops and sells products in three main markets: pharmaceuticals (50%… Read More

Latest pharma spinoff should pay off

Johnson & Johnson recently announced that it would spin off its consumer drug business as a separate firm. This follows several other big pharmaceutical firms, including Pfizer, GlaxoSmithKline and Merck, that have completed similar spinoffs.
The breakup will let Johnson & Johnson focus on its more-profitable… Read More

Spinoff and activist will benefit Glaxo

Pharmaceutical giant GlaxoSmithKline has stayed in an narrow range of $33 to $48 in the past five years as it struggled with high costs and poor acquisitions.
The company now plans to re energize its growth by spinning off its consumer business as a separate company… Read More